[go: up one dir, main page]

MX2019011058A - Moleculas probioticas para reducir virulencia patogena. - Google Patents

Moleculas probioticas para reducir virulencia patogena.

Info

Publication number
MX2019011058A
MX2019011058A MX2019011058A MX2019011058A MX2019011058A MX 2019011058 A MX2019011058 A MX 2019011058A MX 2019011058 A MX2019011058 A MX 2019011058A MX 2019011058 A MX2019011058 A MX 2019011058A MX 2019011058 A MX2019011058 A MX 2019011058A
Authority
MX
Mexico
Prior art keywords
reduce pathogenic
probiotic molecules
pathogenic virulence
peptides
virulence
Prior art date
Application number
MX2019011058A
Other languages
English (en)
Inventor
Angela Cella Monica
M Curtis Sarah
Patrick Roepke Jonathon
Original Assignee
Microsintesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microsintesis Inc filed Critical Microsintesis Inc
Publication of MX2019011058A publication Critical patent/MX2019011058A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/195—Proteins from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)

Abstract

Se proporcionan péptidos derivados de bacterias probióticas que se utilizan para prevenir y/o tratar infecciones no entéricas en un sujeto. Los péptidos derivados de las bacterias probióticas también tienen uso para reducir la virulencia de las infecciones no entéricas en un sujeto. También se proporcionan composiciones de los péptidos formulados como o dentro de productos alimenticios, bebidas, suplementos nutricionales, medicamentos y similares.
MX2019011058A 2017-03-16 2018-03-16 Moleculas probioticas para reducir virulencia patogena. MX2019011058A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472061P 2017-03-16 2017-03-16
PCT/CA2018/050320 WO2018165765A1 (en) 2017-03-16 2018-03-16 Propiotic molecules for reducing pathogen virulence

Publications (1)

Publication Number Publication Date
MX2019011058A true MX2019011058A (es) 2019-12-09

Family

ID=63521745

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011058A MX2019011058A (es) 2017-03-16 2018-03-16 Moleculas probioticas para reducir virulencia patogena.

Country Status (16)

Country Link
US (3) US11912788B2 (es)
EP (1) EP3595698A4 (es)
JP (2) JP2020510096A (es)
KR (2) KR20190140443A (es)
CN (1) CN110621332A (es)
AU (2) AU2018233183A1 (es)
BR (1) BR112019019256A2 (es)
CA (1) CA3056719A1 (es)
CL (1) CL2019002640A1 (es)
EA (1) EA201992176A1 (es)
MA (1) MA51873A (es)
MX (1) MX2019011058A (es)
PE (1) PE20191783A1 (es)
PH (1) PH12019502340A1 (es)
SG (1) SG11201909606RA (es)
WO (1) WO2018165765A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3596103A4 (en) * 2017-03-16 2021-01-20 Microsintesis Inc. Compositions and methods involving probiotic molecules
CA3056719A1 (en) 2017-03-16 2018-09-20 Microsintesis Inc. Probiotic molecules for reducing pathogen virulence
AU2020299061A1 (en) * 2019-07-02 2022-02-10 Microsintesis Inc. Quorum-sensing inhibitors and/or postbiotic metabolites and related methods
CN115039885B (zh) * 2021-05-14 2023-11-03 江苏艾兰得营养品有限公司 一种具有抑制奇异变形杆菌生长作用的副干酪乳杆菌及其益生菌组合物、发酵液和应用
CA3150903C (en) * 2021-05-14 2025-05-27 Ivc Nutrition Corporation PROBIOTIC TO INHIBIT THE GROWTH OF PROTEUS MIRABILIS AND FERMENTATION BROTH AND RELATED APPLICATION
KR102337951B1 (ko) * 2021-06-25 2021-12-13 주식회사 비피도 요로감염 개선, 예방 또는 치료를 위한 락토바실러스 헬베티쿠스 gut10 균주 및 이를 포함하는 조성물
KR102356423B1 (ko) * 2021-07-02 2022-02-09 (주)에스디생명공학 항균, 피부 보습, 항아토피, 피부 장벽 강화, 및 주름 개선 활성을 갖는 복합 균주를 유효성분으로 포함하는 조성물
KR102618322B1 (ko) * 2021-10-08 2023-12-27 순천향대학교 산학협력단 신규한 락토 바실러스 균주, 및 이를 포함하는 결핵 예방, 치료, 또는 개선용 조성물
CN114106096A (zh) * 2021-11-16 2022-03-01 华南理工大学 一种具有改善睡眠活性的六肽及其应用
CN114591879B (zh) * 2022-05-11 2022-12-06 中国农业大学 一种抑制幽门螺杆菌的发酵乳杆菌及其应用
KR102551065B1 (ko) * 2022-05-12 2023-07-03 중앙대학교 산학협력단 김치로부터 유래된 LAB(lactic acid bacteria)을 유효성분으로 포함하는 항-바이오필름 조성물
CN116478882A (zh) * 2023-05-05 2023-07-25 石河子大学 能够提高绵羊日增重和饲料转化率的产酸的混合菌制剂的制备方法
CN119242516A (zh) * 2024-10-31 2025-01-03 广西民族大学 一株粪稳杆菌gxun3754及其在防治象耳豆根结线虫上的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69024400T2 (de) 1989-04-28 1996-06-27 Takara Shuzo Co Dem menschlichen Calpastatin ähnliches Polypeptid
FR2686085B1 (fr) 1992-01-10 1995-08-04 Agronomique Inst Nat Rech Peptides representant des fragments du cmp, anticorps diriges contre lesdits peptides, et leurs utilisations.
WO1994018832A1 (en) 1993-02-26 1994-09-01 Dana-Farber Cancer Institute, Inc. Cd4 mediated modulation of lipid kinases
US7393663B2 (en) 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
WO2004092206A1 (ja) 2003-04-14 2004-10-28 Meiji Dairies Corporation 新規ペプチドおよび免疫賦活剤、機能性食品ならびに機能性食品の製造方法
DE10317870A1 (de) * 2003-04-17 2004-11-04 Crompton Vinyl Additives Gmbh Neues Stabilisatorsystem zur Stabilisierung von halogenhaltigen Polymeren
WO2005079210A2 (en) * 2003-12-04 2005-09-01 Biofilms Strategies, Inc. Methods and compositions for preventing biofilm formations, reducing existing biofilms, and for reducing existing biofilms, and for reducing populations of bacteria
US7306677B2 (en) * 2004-01-30 2007-12-11 Boston Scientific Corporation Clamping fixture for coating stents, system using the fixture, and method of using the fixture
ATE542896T1 (de) 2004-12-23 2012-02-15 Campina Nederland Holding Bv Mit dpp-iv hemmenden peptiden angereichertes proteinhydrolysat und deren verwendung
WO2007057872A2 (en) 2005-11-21 2007-05-24 Teagasc-National Diary Products Research Centre Casein-derived antimicrobial peptides and lactobacillus strains that produce them
US8431528B2 (en) 2008-05-16 2013-04-30 University Of Maryland, Baltimore Antibacterial Lactobacillus GG peptides and methods of use
WO2009155711A1 (en) * 2008-06-27 2009-12-30 University Of Guelph Analysis of lactobacillus acidophilus la-5 signal interference molecules
EP4012714A1 (en) 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
PT105073A (pt) 2010-04-26 2011-10-26 Consejo Superior Investigacion Processo de obtenção de extractos peptídicos bioactivos através da hidrólise de proteínas de soro de leite com enzimas de cynara cardunculus, referidos extractos e respectivas utilizações
WO2014020209A1 (es) 2012-07-30 2014-02-06 Consejo Superior De Investigaciones Científicas (Csic) Uso de hidrolizados de proteínas lácteas como protectores a nivel gastrointestinal
SG11201500111VA (en) * 2012-08-29 2015-03-30 Agency Science Tech & Res Peptides and uses thereof
WO2014033281A1 (en) 2012-08-31 2014-03-06 Westfaelische Wilhelms-Universitaet Muenster Methods and peptides for preventing and treating a bcr-abl and a c-abl associated disease
EP3033351A4 (en) 2013-08-12 2017-03-22 Mansel Griffiths Antiviral methods and compositions comprising probiotic bacterial molecules
US20160303182A1 (en) * 2013-10-31 2016-10-20 Hutchison Biofilm Medical Solutions Limited Use of peptides in antibiotic resistance
CN108513593A (zh) 2015-04-23 2018-09-07 南托米克斯有限责任公司 癌症新表位
CA3056719A1 (en) 2017-03-16 2018-09-20 Microsintesis Inc. Probiotic molecules for reducing pathogen virulence
EP3596103A4 (en) 2017-03-16 2021-01-20 Microsintesis Inc. Compositions and methods involving probiotic molecules

Also Published As

Publication number Publication date
AU2022203650B2 (en) 2024-04-11
CN110621332A (zh) 2019-12-27
EP3595698A4 (en) 2020-12-23
US20240150399A1 (en) 2024-05-09
WO2018165765A1 (en) 2018-09-20
US20250313595A1 (en) 2025-10-09
BR112019019256A2 (pt) 2020-04-14
CA3056719A1 (en) 2018-09-20
PE20191783A1 (es) 2019-12-24
SG11201909606RA (en) 2019-11-28
CL2019002640A1 (es) 2020-05-15
AU2018233183A1 (en) 2019-10-31
EP3595698A1 (en) 2020-01-22
JP2020510096A (ja) 2020-04-02
KR20240046640A (ko) 2024-04-09
PH12019502340A1 (en) 2020-10-19
WO2018165765A9 (en) 2018-11-22
MA51873A (fr) 2020-01-22
EA201992176A1 (ru) 2020-03-04
AU2022203650A1 (en) 2022-06-16
JP2023036938A (ja) 2023-03-14
US11912788B2 (en) 2024-02-27
KR20190140443A (ko) 2019-12-19
US20200017547A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
MX2019011058A (es) Moleculas probioticas para reducir virulencia patogena.
SA517381819B1 (ar) التعديل المناعي
CY1122191T1 (el) Βακτηριο για χρηση ως προβιοτικο για διατροφικες και ιατρικες εφαρμογες
AR110684A1 (es) Composiciones que comprenden cepas bacterianas y método de tratamiento
EA201391500A1 (ru) Синергический противомикробный эффект
MY188541A (en) Besifloxacin for the treatment of resistant acne
BRPI1010637A2 (pt) suplementos nutricionais orais compreendendo probióticos
MX2018002543A (es) Composiciones que comprenden compuestos de urolitina.
MY197201A (en) Novel probiotics bifidobacteria strains
PE20191785A1 (es) Composiciones y metodos que involucran moleculas probioticas
MY187060A (en) Bifidobacteria as probiotic foundation species of gut microbiota
PH12018500666A1 (en) Oat-based product and process of manufacture
PH12018550110A1 (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
MX2019005535A (es) Streptococcus thermophilus para uso en la preparación de productos fermentados.
MX2017007969A (es) Bacterias de acido lactico y su uso para el tratamiento de mastitis.
SG10201908193PA (en) Nucleotide composition and application in food thereof
PH12018502181B1 (en) Formulation systems for antimicrobial glycolipids
PL414701A1 (pl) Nowy szczep Lactobacillus plantarum AMT14 i kompozycja zawierająca szczep Lactobacillus plantarum AMT14
PH12016501947B1 (en) Gender specific synthetic nutritional compositions and nutritional systems comprising them
MX2020001501A (es) Streptococcus australis como bioterapeuticos.
WO2015187638A3 (en) Method of reducing e. coli or salmonella contamination of agricultural products
MX2020007906A (es) Composicion que comprende nuevas cepas de lactobacillus salivarius y metodo para la prevencion y el tratamiento de otitis e infecciones respiratorias de vias altas.
RU2015107472A (ru) Штамм бактерий Lactobacillus acidophilus Т-193, используемый при приготовлении ацидофильной закваски ("Ульцерин"), а также других лечебно-профилактических продуктов для лечения дисбактериоза и его последствий
MX2019014359A (es) Composicion colorante que comprende fosfato tricalcico como agente colorante blanco.
AR107805A1 (es) Composiciones que comprenden cepas bacterianas